7,12-Dimethylbenz[a]anthracene

About: 7,12-Dimethylbenz[a]anthracene is a research topic. Over the lifetime, 1717 publications have been published within this topic receiving 40892 citations.

The aspirin metabolite, salicylate, inhibits 7,12-dimethylbenz[a]anthracene-DNA adduct formation in breast cancer cells.

Abstract: There is evidence that aspirin and other non-steroidal anti-inflammatory drugs may be protective agents against cancer in the gastrointestinal tract. These effects are particularly well documented for the colon and rectum. Some epidemiological and experimental studies have suggested that aspirin could also be a chemopreventive agent against breast cancer. We investigated the effects of the aspirin metabolite, salicylate (SA), on 7,12-dimethylbenz[a]anthracene (DMBA)-DNA adduct formation as well as on the expression of the enzymes involved in the carcinogen bioactivation pathway, in particular cytochrome P450 1A (CYP1A) and cyclooxygenases (COX-1 and COX-2). The effects of the test drug were examined in both the human mammary carcinoma cell line, MCF-7, and mammary cells derived from DMBA-induced rat mammary tumours (RMTCs). In this study, we also reported the effects of SA on cell growth and viability in breast cancer cells (BCCs). The results demonstrated that DMBA-DNA adduct formation in both cancer cell lines was inhibited by SA at concentrations of > or = 2.5 mM. CYP1A was undetectable in RMTCs while CYP1A induction by beta-naphthoflavone in MCF-7 cells was significantly inhibited by SA in a concentration-dependent manner. Aspirin did not affect COX-1 expression in either of the BCCs. COX-2 was not detected in MCF-7 cells, but its expression in RMTCs was inhibited by SA treatment, which also significantly reduced BCC growth, but failed to cause cell death by necrosis or apoptosis. These data suggest that inhibition of DMBA-DNA adduct formation may contribute to aspirin breast cancer chemopreventive action and indicate that this drug can act in the first stage of carcinogenesis.

Impact of Obesity on Ovotoxicity Induced by 7,12-dimethylbenz[a]anthracene in Mice

Abstract: Insulin, elevated during obesity, regulates xenobiotic biotransformation enzymes, potentially through phosphatidylinositol 3-kinase (PI3K) signaling, in extraovarian tissues. PI3K regulates oocyte viability, follicular activation, and ovarian chemical biotransformation. 7,12-Dimethylbenz[a]anthracene (DMBA), a carcinogen and ovotoxicant, destroys all stages of follicles, leading to premature ovarian failure. Obesity has been reported to promote DMBA-induced tumors, but it remains unknown whether obesity affects ovarian xenobiotic metabolism. Therefore, we investigated ovarian expression of xenobiotic metabolism genes—microsomal epoxide hydrolase (Ephx1), glutathione S-transferase (GST) class Pi (Gstp1) and class mu 1 (Gstm1), and PI3K-signaling members (protein kinase B [AKT] alpha [Akt1], beta [Akt2], and the forkhead transcription factor subfamily 3 [Foxo3])—in lean and obese female mice after DMBA exposure (1 mg/kg; intraperitoneal injection for 14 days). Relative to lean, obese mice had decreased (P < 0.05) healthy primordial and primary follicle numbers but increased (P < 0.05) secondary and preovulatory follicles numbers. Obesity increased (P < 0.05) Akt1, Akt2, Gstm1, and Ephx1 mRNA and pAKTSer473/Thr308, GSTM1, GSTP1, and EPHX1 protein levels. DMBA decreased (P < 0.05) ovarian weight in lean and obese mice, however, obese DMBA-treated females had a greater reduction (P < 0.05) in ovarian weight. In both lean and obese mice, DMBA decreased (P < 0.05) all stages of healthy follicle numbers, increased Gstp1 and Ephx1 mRNA as well as GSTM1, GSTP1, and EPHX1 protein levels, and decreased Akt1 and Akt2 mRNA as well as pAKTSer473 or pAKTThr308, FOXO3, and pFOXO3Ser253 protein expression. There was an additive effect between obesity and DMBA exposure for increased Gstm1 and Ephx1 mRNA as well as GSTM1 and EPHX1 protein expression.

Lymphocyte mutant frequency in relation to DNA adduct formation in rats treated with tumorigenic doses of the mammary gland carcinogen 7,12-dimethylbenz[a]anthracene.

Abstract: The ability of the rat lymphocyte hprt assay to detect tissue-specific carcinogens was evaluated using 7,12-dimethylbenz[a]anthracene (DMBA) administered under conditions that result in mammary gland tumors. Fifty-day-old female Sprague-Dawley rats were given single doses of 5 and 20 mg/kg DMBA by gavage, and the frequency of 6-thioguanine-resistant (TGr) T-lymphocytes was measured over a period of 21 weeks. A time- and dose-dependent increase in mutant frequency was found, with a maximum frequency found 9-15 weeks after treatment with 20 mg/kg of DMBA. Rats were also dosed with 1, 2.5, 5, 10, 15 and 20 mg/kg of DMBA and assayed for TGr mutant frequency 10 weeks after treatment. A significant linear dose-response was found, with all the DMBA doses resulting in significant increases in mutant frequency. To determine whether or not DMBA-induced mutants in rat lymphocytes reflected the DNA damage in the target tissue, rats were treated with 5 and 20 mg/kg of DMBA and spleen lymphocytes and mammary gland tissue were assayed for DNA adduct formation 1, 3 and 7 days later. A similar pattern of 32P- postlabeled adducts, involving both dG and dA nucleotides, was found in DNA from both the target tissue and the surrogate lymphocytes. Adduct formation was dose responsive in both tissues, with a 2.3- to 4-fold higher concentration in mammary gland as compared with lymphocytes. These results indicate that the rat lymphocyte hprt assay is sensitive to a mammary gland carcinogen and that similar types of DNA adducts are associated with both the lymphocyte mutants and the mammary gland tumors induced by DMBA.

DNA fingerprinting of 7,12-dimethylbenz[a]anthracene-induced and spontaneous CD-1 mouse liver tumors.

Abstract: Determining to what degree chemicals and environmental agents contribute to the development of cancer would be materially enhanced by the ability to distinguish chemically induced tumors from those that arise spontaneously. Using DNA fingerprinting as an assay, we investigated whether somatic DNA rearrangements are more frequent in chemically induced mouse liver tumors than they are in spontaneous mouse liver tumors. Tumors were induced by a single i.p. injection of 12-day old male Crl:CD-1(ICR)BR (CD-1) mice with 20 nmol/g 7,12-dimethylbenz[a]-anthracene and were harvested 9 to 12 months after injection. Spontaneous tumors were obtained from 94- to 98-week old male CD-1 mice. We detected 8 rearrangements in 14 7,12-dimethylbenz[a]anthracene-induced tumors, which corresponds to a high rearrangement frequency of about 2% (of the minisatellite bands examined). Furthermore, 6 of these rearrangements included complete band losses which must have occurred early in tumor development. However, only 2 band changes were observed in 15 spontaneous tumors, and both changes were intensity shifts which may represent rearrangements that occurred later during tumor progression. Histological examination showed that the higher frequency of rearrangements in 7,12-dimethylbenz[a]anthracene-induced tumors versus spontaneous tumors was not related to differences in the degree of tumor progression or malignancy. Our results suggest that DNA fingerprinting may be a valuable assay for differentiating certain chemically induced tumors from spontaneous tumors.

7,12-Dimethylbenz [a] anthracene-DNA adducts in Sprague-Dawley and Long-Evans female rats: the relationship of DNA adducts to mammary cancer

Abstract: 7,12-Dimethylbenz[a]anthracene (DMBA) is a powerful carcinogen to the mammary gland of the pubescent female Sprague-Dawley (S.D.) rat but is a much less potent inducer of mammary adenocarcinoma in the female Long-Evans (L.E.) rat of the same age. The livers of both strains are refractory to DMBA. The maximum levels of DMBA--DNA adducts formed, in both the mammary gland and liver following i.p. administration of [3H]DMBA (21 mumol) were significantly higher (p less than 0.01) in the resistant L.E. strain than the sensitive S.D. strain. Maximal levels of DMBA--DNA adducts were observed at approximately 48 h post administration of the hydrocarbon for both organs of both strains. For the S.D. animals no significant loss of adducts (relative to the 48 h maxima) was observed from either organ at the last time point (336 h). In contrast both organs of the L.E. strain showed some evidence of adduct removal. Analysis of the DMBA--deoxyribonucleoside adducts by h.p.l.c. following enzymatic hydrolysis of the purified DNA showed that A-ring diol-epoxide adducts of both DMBA and a major metabolite 7-hydroxymethyl-12-methylbenz[a]anthracene (7OHM-12MBA) were present in both organs from both strains. In both strains the levels of 7OHM-12MBA adducts were less, relative to the DMBA adducts, in the mammary gland than in the liver. With respect to specific adduct removal, L.E. animals removed approximately 70% of the identifiable adducts from the liver DNA in the 48 h to 336 h (12 d) time period. In contrast the S.D. animals showed no such capability for removing these adducts during this same time frame. These observations indicate that some factor(s) in addition to, or in conjunction with, the levels of DMBA--DNA adducts initially formed are responsible for the overall relative sensitivities of the S.D. and L.E. mammary gland to this hydrocarbon. One such parameter might be the relative propensity for specific adduct removal or the relative capacity of the two strains to repair DMBA-induced DNA damage.